High levels of BRC4 induced by a Tet-On 3G system suppress DNA repair and impair cell proliferation in vertebrate cells  by Abe, Takuya & Branzei, Dana
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Transient  induction  or  suppression  of  target  genes  is  useful  to study  the  function  of toxic  or  essential
genes  in  cells.  Here  we  apply  a Tet-On  3G system  to  DT40  lymphoma  B  cell  lines,  validating  it for  three
different  genes.  Using  this  tool,  we  then  show  that overexpression  of the  chicken  BRC4  repeat  of  the tumor
suppressor  BRCA2  impairs  cell  proliferation  and  induces  chromosomal  breaks.  Mechanistically,  high  lev-
els of  BRC4  suppress  double  strand  break-induced  homologous  recombination,  inhibit  the  formation  of
RAD51  recombination  repair  foci,  reduce  cellular  resistance  to  DNA  damaging  agents  and  induce  a  G2
damage  checkpoint-mediated  cell-cycle  arrest.  The  above  phenotypes  are  mediated  by BRC4  capability  to
bind  and inhibit  RAD51.  The  toxicity  associated  with  BRC4  overexpression  is  exacerbated  by  chemother-
apeutic  agents  and  reversed  by RAD51  overexpression,  but it is neither  aggravated  nor  suppressed  by a
deﬁcit  in  the  non-homologous  end-joining  pathway  of  double  strand  break  repair.  We  further  ﬁnd  thatet-On system
T40 cells
the  endogenous  BRCA2  mediates  the  cytotoxicity  associated  with  BRC4  induction,  thus  underscoring  the
possibility  that  BRC4  or other  domains  of  BRCA2  cooperate  with  ectopic  BRC4 in  regulating  repair  activ-
ities  or  mitotic  cell  division.  In all,  the results  demonstrate  the utility  of the Tet-On  3G system  in  DT40
research  and  underpin  a model  in which  BRC4  role  on cell proliferation  and  chromosome  repair  arises
primarily  from  its  suppressive  role  on RAD51  functions.
©  2014  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND. Introduction
Homologous recombination (HR) is essential for genome
ntegrity as it protects against DNA lesions derived from both
ndogenous and exogenous sources. The recombination mediator
AD51, the homologue of yeast Rad51 and bacterial RecA, plays
entral roles in HR in all organisms studied to date. Its coating
f single strand (ss) DNA, exposed at stalled replication forks or
ormed during resection of double strand breaks (DSBs), leads to
he formation of a nucleoprotein ﬁlament that can invade a homol-
gous duplex to promote DNA repair [1]. HR and RAD51 activities
eed to be tightly regulated in the cell: low levels of RAD51 cause
hromosome breakage and reduced cell proliferation, but increased
evels of RAD51 also lead to genomic rearrangements by its abil-
ty to induce aberrant or ectopic recombination with repeats or
on-homologous chromosomes [2,3].
The BRCA2 tumor suppressor, which is associated with a sub-
tantial fraction of familial breast cancers, participates in DNA
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recombination and repair processes, and is well known for its
recombination mediator function [4]. Critical for the function of
BRCA2 is its interaction with RAD51 [4–8], which is largely medi-
ated by the eight internal BRC repeats contained in BRCA2 [9,10]. Of
these BRC repeats, BRC3 and BRC4 have been thoroughly character-
ized biochemically. They bind to RAD51 [5,7,8,10,11], and whereas
low concentrations of BRC4 and BRC3 enhance RAD51 binding to
ssDNA and stimulate RAD51-mediated strand exchange [10,12,13],
high concentrations of BRC4 and BRC3 disrupt RAD51 ﬁlament
formation [6,11,12]. Consistent with these in vitro biochemical
observations, both BRCA2 knockout cells and BRC4 overexpress-
ing cells are defective in RAD51 foci formation and HR repair
[7,8,14,15].
In this study, we  examined the function of BRC4 on HR by
conditionally overexpressing BRC4 in chicken DT40 cells using a
tetracycline-inducible Tet-On 3G system. The Tet-On system is
especially useful when applied to cell lines in which the transfec-
tion efﬁciency of expression plasmids is low, as is the case of nerve
and lymphocyte cell lines. While the bursal DT40 cell line has mul-
tiple valuable features for research [16], the transfection efﬁciency
of expression plasmids is usually very low. Here, we employed a
recently developed Tet-On 3G system and applied it to p53, pre-
supposed to induce apoptosis-mediated cell cycle arrest, and to
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Table 1
Cell lines used in this study.
Genotype Selective marker Reference
WT CL18 [16]
WT + DR-GFP + I-SceI (Tet-On) Puro/Neo This study
WT  + DR-GFP + I-SceI and BRC4 (Tet-On) Puro/Neo/Bsr This study
WT  + BRC4 (Tet-On) Neo This study
WT  + BRC4 A1504S (Tet-On) Bsr This study
WT  + BRC4 (Tet-On) + hsRAD51 Neo/Bsr This study
BRCA2+/− Bsr/Puro [15]
BRCA2+/− + BRC4 (Tet-On) Bsr/Puro/Neo This study
XRCC4/− + DR-GFP + I-SceI (Tet-On) Neo/Puro/His This study
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GXRCC4/ + BRC4 (Tet-On) Puro/Neo/His This study
XRCC3−/− Bsr/His [17]
RAD51−/− + hsRAD51 Puro/Bsr/Neo/Hyg [18]
RC4 and I-SceI to study their effect on recombinational repair. In
ll cases, we achieved high enough induction to cause cell death in
he presence of doxycycline (Dox) and detected no leaky expression
n its absence, thus demonstrating the general utility of the Tet-On
G system in DT40 research for studies of conditional or transient
nduction of genes.
Using these new tools, here we report that conditional induc-
ion of the BRC4 repeat of BRCA2 impairs cell proliferation of
hicken DT40 cells by inducing a G2 damage checkpoint-mediated
rrest and an accumulation of chromosome gaps and breaks.
RC4 induction suppresses HR and reduces cellular resistance
o DNA damaging agents. These effects are mediated by BRC4
inding to RAD51 and counteracted by RAD51 overexpression.
on-homologous end joining (NHEJ) was not responsible for the
henotypes associated with BRC4 induction, nor was required to
ustain viability in these cells, indicating that NHEJ is actively sup-
ressed in G2 even when the HR pathway is defective. Moreover,
e ﬁnd that endogenous BRCA2 is required for BRC4 cytotoxic-
ty, suggesting a possible crosstalk between BRC4 and other BRCA2
omains in regulating DNA repair or mitotic cell division.
. Materials and methods
.1. Cell culture techniques and cell viability/drug sensitivity
ssays
Cells were cultured at 39.5 ◦C in D-MEM/F-12 medium
Gibco) supplemented with 10% fetal bovine serum, 2% chicken
erum (Sigma), Penicillin/Streptomycin mix, and 10 M 2-
ercaptoethanol (Gibco) in the presence or absence of 1 g/ml
ox. The cell lines used in this study are shown in Table 1. To
lot growth curves, each cell line was cultured in three different
ells of 24 well-plates and passaged every 12 h. Cell number was
etermined by ﬂow cytometry using plastic microbeads (07313-5;
olysciences). Cell solutions were mixed with the plastic microbead
uspension at a ratio of 10:1, and viable cells determined by for-
ard scatter and side scatter were counted when a given number
f microbeads were detected by ﬂow cytometry. mCherry positive
ells were detected by FL2-H as shown in Fig. 2A.
.2. Plasmid construction and transfection
Tet-On® 3G Inducible Expression System (with mCherry)
ontaining pTRE3G-mCherry and pCMV-Tet3G vectors was  pur-
hased from Clontech. Chicken BRC4 cDNA was prepared by reverse
ranscription PCR using 5′-GGAACTTATCTGACTGGTTTCTGTACTGC-
′ (sense) and 5′-ATCTGCATCACAATGAGCAGTACTGTCC-3′antisense) primers. The NdeI site and NLS to its N-
erminal end and a FLAG tag and BamHI site to its
-terminal end were added by PCR using 5′-CATATGCCAAA
AAGAAACGCAAGGTGGGAACTTATCTGACTGGTTTCTGTACTGC-3′ir 22 (2014) 153–164
(sense) and 5′-GGATCCTTACTTGTCGTCATCGTCTTTGTAGTCTGCATC
ACAATGAGCAGTACTGTCC-3′ (antisense) primers. BRC4 was
then cloned into the pTRE3G-mCherry vector. The amino
acid sequence of BRC4 used in this study except for NLS
and FLAG is GTYLTGFCTASGKKITIADGFLAKAEEFFSENNVDL-
GKDDNDCFEDCLRKCNKSYVKDRDLCMDSTAHCDAD (amino acid
residues 1495–1566 of chicken BRCA2). Similarly, p53 cDNA was
ampliﬁed using 5′-GAATTCCGAACGGCGGCGGCGGC-3′ (sense)
and 5′-GCTGAAGGGAAAGGGGGCGTGGTAAAGG-3′ (antisense)
primers, then an NdeI site to its N-terminal and a FLAG tag
and BamHI site to its C-terminal were added by PCR using
5′-CATATGGCGGAGGAGATGGAACCATTGCTGG-3′ (sense) and 5′-
GGATCCTTACTTGTCGTCATCGTCTTTGTAGTCCATGTCCGAGCCTTTTT
GCAGCAGTTTCTTCC-3′ (antisense) primers. After cloning p53
into the pTRE3G-mCherry vector, the premature stop codon
of p53 was  corrected by site directed mutagenesis using
5′-CTGTTGGGGCGGCGCTGCTTCGAGGTGCGC-3′ (sense) and
5′-GCGCACCTCGAAGCAGCGCCGCCCCAACAG-3′ (antisense)
primers. I-SceI was  tagged with an NdeI site N-terminally
and a FLAG and BamHI site C-terminally by PCR using
5′-CATATGGGATCAAGATCGCCAAAAAAGAAGAG-3′ (sense) and 5′-
GGATCCTTACTTGTCGTCATCGTCTTTGTAGTCCATTTTCAGGAAAGTTT
CGGAGGAGATAGTG-3′ (antisense) primers, and cloned into the
pTRE3G-mCherry vector. These expression vectors were trans-
fected to DT40 cells with pCMV-Tet3G vectors in the ratio (6:1),
and cells expressing the target genes in the presence of Dox
were selected. BRC4-A1504S cells were obtained by transfecting
an identical BRC4 construct containing the A1504S mutation
engineered by QuickChange Site Directed Mutagenesis using
5′-CTGACTGGTTTCTGTACTTCTAGTGGCAAG-3′ (sense) and 5′-
CTTGCCACTAGAAGTACAGAAACCAGTCAG-3′ (antisense) primers.
hsRAD51 overexpression clones were obtained as previously
described [17]. The XRCC4 knockout constructs are previously
reported [19]. Brieﬂy, the 110–165 amino acid fragment of XRCC4
(full length 283 amino acids) was  replaced by drug resistance
marker genes.
2.3. DNA fragmentation assay
DNA fragmentation assay was  performed as previously
described [19]. Cells were lysed, and genomic DNA was  extracted
using Easy DNA kit (Invitrogen) according to the manufacturer’s
protocol. DNA was  quantiﬁed and 4 g was electrophoresed in a 2%
agarose gel containing ethidium bromide (0.5 g/ml). DNA  ladders
were visualized under an ultraviolet light and photographed.
2.4. Western blotting
Western blotting were performed as previously described [19]
using antibodies against MCM7  or RAD51 (Santa Cruz), -tubulin
or FLAG-M2 (Sigma), pCHK1 S345 (Cell Signaling), -H2AX (Milli-
pore) followed by horseradish peroxidase-conjugated anti-rabbit,
anti-rabbit, or anti-mouse IgG secondary antibody (Cell Signaling).
Proteins were visualized using SuperSignal West Femto Maximum
Sensitivity Substrate (Thermo Scientiﬁc).
2.5. Cell cycle analysis by ﬂow cytometry
Flow cytometry was performed as previously described [18].
Cells were cultured in the presence of BrdU for 15 min, ﬁxed in 70%
ethanol, incubated with anti-BrdU antibody (BD Biosciences), and
stained with FITC-conjugated anti-mouse IgG antibody (Sigma) and
propidium iodide. For PI single staining analysis, cells were ﬁxed in
70% ethanol and stained with propidium iodide.
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.6. mRNA isolation, reverse transcription and qPCR
Total RNA was isolated using TRIzol reagent (Invitrogen) and
onverted to cDNA with Superscript III (Invitrogen). The cDNA
as ampliﬁed with GoTaq® qPCR Master Mix  (Promega) and
ightCycler® 480 system (Roche). Normalization of the amount
f cDNA was done with ˇ-actin. The primers used to amplify
RC4 were 5′-CAATTGCTGATGGATTTTTGGC-3′ (sense) and 5′-
TCACGGTCTTTAACATAGC-3′ (antisense), and the primers used to
mplify ˇ-actin were 5′-CGTGCTGTGTTCCCATCTATCGTG-3′ (sense)
nd 5′-TACCTCTTTTGCTCTGGGCTTCATC-3′ (antisense).
.7. Immunoﬂuorescent visualization of subnuclear RAD51 foci
ormation
Immunocytochemical analysis was performed as described
n [17]. Brieﬂy, DT40 cells (105 cells) were treated with MMC
500 ng/ml) for 1 h, washed with warm medium 3 times and cul-
ured for an additional 1 h at 39.5 ◦C. Cells were washed with
BS and spun onto Nunc® Lab-Tek® II Chamber Slide system by
entrifugal attachment. Cells were ﬁxed with 4% formaldehyde
or 15 min  at room temperature, and permeabilized with 0.5%
riton/PBS. After blocking with 3% BSA, ﬁxed cells were treated
ith RAD51 antibodies (1:500; Santa Cruz) followed by Alexa488-
onjugated anti-rabbit IgG (1:100; Molecular Probes). In Fig. 8D
nd E, in order to detect RAD51 foci even in the presence of
verexpressed RAD51,  cells were treated with MMC  for 6 h and pre-
xtracted by 0.1% triton/PBS for 3 min  prior to ﬁxation. At least 100
orphologically intact cells were examined. Cells with more than
our brightly ﬂuorescing foci were scored as positive.
. Results
.1. Establishment of the Tet-On 3G system in DT40 cells
To establish a good conditional expression system in DT40 cells,
e applied the newly developed Tet-On 3G system in which both
he tetracycline response elements present in the promoter [20]
nd the tetracycline-controlled transactivator protein [21] were
ptimized to achieve low background and high expression. We  ﬁrst
xamined the effects of expressing p53, thought to be inactive in
T40 cells [22]. p53 expression is likely detrimental to DT40 cell
roliferation by inducing apoptosis, similarly to its effect in other
ancer cell lines [23]. To this purpose, we cloned ampliﬁed chicken
53 using a DT40 cDNA library made by the reverse transcription
eaction. Cloned p53 was sequenced and we found mutations in
oth alleles of p53 in DT40 cells. One is a premature stop codon
utation that leads to a C-terminal truncated protein (1–254 amino
cids), the other is a deletion mutation in the C-terminus further
ccompanied by a frame shift (Supplementary Fig. 1). To obtain
ntact chicken p53, the premature stop codon of the ﬁrst allele
f p53 was corrected by site directed mutagenesis and the new
llele was cloned into the pTRE3G mCherry vector, which allows
onitoring of the expression of target proteins by detecting the
oncurrently expressed mCherry. Wild-type (WT) DT40 cells were
o-transfected with p53/TRE3G mCherry construct and the pCMV-
et3G vector, which contains a Neo resistant marker, and several
lones that expressed mCherry after Dox addition were selected.
xpression of p53, induced by addition of Dox, immediately blocked
ell growth (Fig. 1A) and led to apoptosis as detected by DNA ladder
ormation (Fig. 1B). In the absence of Dox, the cells containing Tet-
n-p53 grew as fast as WT  (Fig. 1A). These results indicate that the
et-On 3G system is proﬁcient at inducing p53 at levels high enough
o kill DT40 cells. In addition, no detectable leaky expression ofir 22 (2014) 153–164 155
p53 in the absence of Dox was  observed as assessed by examining
protein levels by Western blotting (Fig. 1C).
3.2. Measurement of HR-dependent DSB repair using Tet-On 3G
I-SceI system
By using a similar approach, we  next expressed I-SceI, a hom-
ing endonuclease commonly used in various reporter assay (such
as DR-GFP) that are based on induced DSBs at I-SceI sites [24].
Repair by HR restores a functional cassette, in this case GFP, the
expression levels of which can be conveniently monitored via FACS.
In these assays, I-SceI is usually introduced by transfection. How-
ever, the transfection efﬁciency varies greatly with the cell line
and the transfection procedure itself causes cytotoxicity. Further-
more, the expression levels of I-SceI in each cell are not constant,
being dependent on the level of transfected plasmids. To overcome
these caveats, we applied the Tet-On 3G system described above
also to I-SceI. After transfection of 30 g of I-SceI/TRE3G mCherry
vector together with 5 g of pCMV-Tet3G vector to 107 of cells
and following drug selection by G418, we got 22 drug resistance
clones, 10 of which expressed mCherry after Dox addition. mCherry
expression ratios of these clones were from 99.26% to 99.9%, 72 h
after Dox addition. None of these clones displayed leaky expres-
sion monitored by mCherry in the absence of Dox. One clone out
of the ten that expressed high levels of mCherry was picked up
and further characterized phenotypically. In the absence of Dox,
no cells expressing mCherry (or I-SceI) could be detected (Fig. 2A).
Addition of Dox, however, induced mCherry on 98.5% of living
population within 48 h (Fig. 2A and B). mCherry induction was
kept in 96.9% of living population even after 120 h (Fig. 2A and
B). Expressed I-SceI efﬁciently elicited recombination in the DR-
GFP construct, making 3.7% of the living population GFP positive
already after 48 h. The induction frequency is much higher than
that induced by transient transfection using the Amaxa Nucleof-
ector, so far thought to achieve maximum transfection efﬁciency
in DT40 cells [24]. Notably, an advantage of the Tet-On 3G sys-
tem is its ability to ensure consistent and continuous expression
levels of I-SceI, compared to the ones achieved by transient trans-
fection [24]. Because the population of GFP positive cells increased
gradually following I-SceI induction (Fig. 2B), we concluded that
most of DSBs are repaired without base pair change and therefore
are likely re-cut by I-SceI again. GFP positive population reached a
plateau around 20%, 8 days after the addition of Dox (Fig. 2B). Likely,
at this time, I-SceI sites were either replaced by upstream donor
sequences (20%) or mutated due to the DSB end processing (the
rest of 80%). DSBs are generally repaired by two major pathways:
NHEJ that ligates broken DNA ends with no regard for homol-
ogy, and by homology-directed repair that relies on DSBs being
processed to expose single strand ends, which can then either
invade homologous double-stranded (ds) DNA, a process known
as HR, or anneal with other homologous ssDNA, a process known
as single-strand annealing [1]. The I-SceI -induced recombination
frequency is highly up-regulated in NHEJ-deﬁcient mutants, sug-
gesting that the DSBs induced by I-SceI are predominantly repaired
by NHEJ in DT40 cells, and in the absence of NHEJ activity, they are
funneled toward HR [25].
To recapitulate this feature in our system, we expressed I-SceI
in the NHEJ mutant XRCC4/− containing the DR-GFP reporter assay.
NHEJ depends on the LigaseIV/XRCC4/XLF ligation complex activity
[26]. We  note that chicken XRCC4 is located on chromosome Z and
therefore only one targeting disruption is enough to obtain XRCC4
deﬁcient cell lines [19]. In line with the notion above on the pre-
dominance of NHEJ in repairing I-SceI -induced DSBs, XRCC4/− cells
showed highly elevated levels of HR, with about 25% of total cell
population being GFP-positive 48 h after I-SceI induction as com-
pared to about 5% in WT  cells (Fig. 2C). Altogether, these results
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Fig. 1. Cellular effects associated with inducible p53 in chicken DT40 cells. (A) Growth curves. WT or WT + p53 (Tet-On) cells (1 × 105) were inoculated in 1 ml  of medium
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ndicate that the Tet-On 3G system is a powerful tool that can be
uccessfully applied to induce the expression of various types of
enes without leaky expression in the absence of Dox.
.3. Characterization of the cytotoxic effect of the BRC4 peptide
With the purpose of examining in vivo the effects of the BRC
epeats of BRCA2 on DNA repair/recombination and cell viabil-
ty, we next applied the Tet-On 3G system to BRC4. The amino
cid sequence identity of chicken BRCA2 with that of the human
omolog is 40%, and while human BRCA2 has eight BRC repeats,
hicken BRCA2 contains only the BRC-1, 2, 4, 7, and 8 repeats [27].
ecause BRC3 and BRC4 repeats in human were characterized bio-
hemically [5,7,8,10,11], but only BRC4 is conserved in chicken, we
hose BRC4 for our study. To this end, the BRC4 peptide was  tagged
ith the SV40 nuclear localization signal (NLS) in its N-terminus
nd with FLAG in its C-terminus, and expressed by the Tet-On 3G
ystem. After transfection, several clones expressing BRC4–FLAG
ere obtained. Hereafter, we refer to these WT  cells containinghe NLS–BRC4–FLAG (Tet-On) construct as ‘BRC4′ cells. Dox addi-
ion efﬁciently induced mRNA and protein of BRC4 cells (Fig. 3A
nd B). The expression level of BRC4 mRNA at 12 h after addition
f Dox is 500 to 1000-fold higher than the one observed without DNA was prepared and subjected to agarose gel electrophoresis. DNA ladders were
r marker. (C) Monitoring of p53-FLAG. Whole cell lysates were prepared from cells
 control) were detected by Western blotting.
Dox (Fig. 3A). We  then examined the growth curve of BRC4 cells
and observed that BRC4 induction severely blocked cell growth
already after one cell-cycle (Fig. 3C). If toxic proteins such as BRC4
are induced over a long time, the rate of Dox resistant popula-
tion appears increased because of the ensuing cell death (Fig. 3B,
48 h time point). To eliminate the Dox resistant population from
our analysis, we  repeated the experiment counting the number
of mCherry expressing cells, which should also express BRC4 pep-
tide simultaneously, and found that BRC4 expressing cells clearly
stopped growing (Fig. 3D).
In addition to cytotoxicity, expression of BRC4 also induced
a large number of chromosomal aberrations of both gap and
break types (Fig. 3E). This phenotype is reminiscent of the chro-
mosomal aberrations accumulating upon inhibition of RAD51 in
vertebrate and murine cells [18,28], although no major effects on
RAD51 levels were observed upon BRC4 induction (data not shown
and see below). DT40 cells knocked out for the essential RAD51
gene, but expressing the Homo sapiens RAD51 transgene (hsRAD51)
under the control of a Tet-repressible promoter, showed a sim-
ilar pattern of chromosomal aberrations with the one observed
upon BRC4 overexpression (Fig. 3E) and [18]). Thus, BRC4 induc-
tion leads to cytotoxicity that is associated with chromosome
aberrations.
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Fig. 2. Measurement of homologous recombination-dependent DSB repair. (A) WT + I-SceI (Tet-On) cells containing the DR-GFP construct were incubated with Dox. mCherry
and  GFP expressing fractions were measured at the indicated time points. The vertical axis represents the expression level of mCherry and horizontal axis represents the
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.4. Characterization of the recombination and proliferation
efects of BRC4 cells
BRC4 binds RAD51, inhibits its polymerization and suppresses
R [6,10]. To address whether inhibition of HR underlies the cyto-
oxicity associated with BRC4 overexpression, we examined the
ffect of BRC4 overexpression on I-SceI -induced HR. To this end,
e constructed cell lines co-expressing I-SceI and BRC4. The HR
requency – assessed as GFP positive cells – was reduced almost
y half in BRC4 cells (Fig. 4A). In addition, BRC4 induction also sup-
ressed RAD51 foci formation both in unperturbed conditions or
itomycin C (MMC)-treated cells (Fig. 4B). Together, these results
ndicate that BRC4 overexpression suppresses HR. To address if
ell-cycle arrest underlies the cytotoxicity associated with BRC4
verexpression, we monitored the cell cycle distribution by FACS
nalysis using the Bromodeoxyuridine (BrdU) antibody and pro-
idium iodide (PI). BRC4 cells showed a prominent G2/M arrest
2 h after Dox addition, with the percentage of subG1 population
ncreasing at later time points (Fig. 4C). To understand whether
RC4 cells arrested in the G2 phase of the cell cycle because of dam-
ge checkpoint activation or rather accumulated in M phase, BRC4
ells were incubated with caffeine, an ATM/ATR inhibitor, 12 h after
ox addition. The G2/M arrest associated with BRC4 overexpress-
on was suppressed by caffeine addition (Fig. 4D), indicating that
he BRC4-induced cell cycle arrest involved the G2/M checkpoint.
e further monitored which branch of the damage checkpoint
s induced upon BRC4 overexpression. BRC4 did not cause ATR-
ependent CHK1 phosphorylation, but induced ATM-dependent
-H2AX phosphorylation [29] (Fig. 4E). These results indicate that
RC4 mainly creates DSBs in G2 without prior activation of the
eplication checkpoint, and that the accumulation of chromosomal
reaks and gaps (see Fig. 3E) triggers ATM-mediated arrest in the
2 phase of the cell cycle. -induced cells and I-SceI negative cells, respectively. (B) The percentage of the cell
3.5. BRC4 cytotoxicity is dependent on the amount of BRCA2
The role of BRCA2 in HR is crucial and very complex. BRCA2
does not simply stimulate RAD51 binding to DNA, but modu-
lates the DNA binding afﬁnity of RAD51 based on the structural
characteristics of DNA [10]. In addition, by keeping RAD51 in a
minimal oligomeric state, the C-terminal domain of BRCA2 also
impinges on RAD51 ability to assemble nucleoﬁlaments required
to initiate HR strand exchange [30–33]. Furthermore, while RAD51
overexpression compensates the deﬁciency in RAD51 paralogs and
BRCA1 in terms of cellular sensitivity to cisplatin (CDDP) and MMC
[17,34], it negatively affects cell growth and aggravates the hyper-
sensitivity of BRCA2tr/− cells (BRC3 truncated BRCA2 mutant) to
genotoxic agents [35]. These observations were interpreted as
to indicate that BRCA2 has a role in suppressing “inappropriate”
binding of RAD51 to DNA, whereas RAD51 paralogs and BRCA1
simply facilitate RAD51 polymerization. This idea, together with
the effects observed following BRC4 induction (Fig. 3), made us
hypothesize that endogenous BRCA2 might also suppress RAD51
function through its BRC repeats and/or C-terminal domain or that
the observed cytotoxicity associated with BRC4 induction might
be dependent on the presence of other BRC repeats or the C-
terminus of BRCA2, proposed to play a regulatory role in BRC
repeat-mediated RAD51 nucleoﬁlament disassembly [31,32] or for-
mation [33].
To test the above hypotheses, we  introduced BRC4 into BRCA2−/+
heterozygous cells as BRCA2−/− cells are very slow growing [15],
making it difﬁcult to evaluate the cytotoxic effects associated with
BRC4. Quantitative real time PCR revealed that two individual
−/+clones of BRCA2 BRC4 cells expressed about half the level of BRC4
mRNA in the absence of Dox (Fig. 5A), indicating that both alleles of
BRCA2 are equally active in DT40 cells. In the presence of Dox, com-
parable levels of BRC4 mRNA and protein were induced in BRCA2−/+
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Fig. 3. High levels of BRC4 cause cytotoxicity. (A) Relative BRC4 expression level measured by quantitative polymerase chain reaction (qPCR). WT,  BRCA2−/− (negative control),
and  individually obtained 2 clones of BRC4 cells (WT  + BRC4 (Tet-On) cells) were incubated in the presence or absence of Dox for 12 h when RNA was isolated and converted
to  cDNA. The cDNA was  ampliﬁed with GoTaq® qPCR Master Mix. (B) Expression of the BRC4–FLAG peptide. Whole cell lysates were prepared from BRC4 #1 cells cultured
in  the presence of Dox for the indicated times. BRC4–FLAG and -tubulin (loading control) were detected by Western blotting. (C) Growth curves. Individually obtained 2
clones  of BRC4 cells (1 × 105) were inoculated in 1 ml  of medium and passaged every 12 h. Dox was added at time 0. (D) Growth curves of mCherry positive cells. The number
of  cells expressing mCherry was counted every 12 h. (E) Number of chromosomal aberrations in RAD51−/− cells expressing hsRAD51 from a Tet-inducible promoter and in
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tRC4  cells after treatment with Dox for 18 h (RAD51 + hsRAD51 cells) or for 24 h 
RC4 cells and BRC4 cells (Fig. 5A and B, 24 h). Notably however,
RCA2−/+ BRC4 cells grew much better than BRC4 cells in the pres-
nce of Dox (Fig. 5C). By eliminating the mCherry negative fraction
and therefore the Dox resistant population), the difference in
rowth became even more prominent (Fig. 5D). The chromosomal
reaks/gaps associated with BRC4 induction were also reduced in
RCA2−/+ cells (Fig. 5E). These results demonstrate that endogenous
RCA2 contributes to BRC4 cytotoxicity, most likely by suppressing
AD51 polymerization or RAD51 nuclear ﬁlament formation.
.6. BRC4 cytotoxicity is independent of the NHEJ pathway
NHEJ acts by joining, often in an error-prone manner, the two
nds of a DSB through the activation of the LigaseIV/XRCC4/XLF
igation complex [26]. We  asked if BRC4-induced DNA dam-
ge/cytotoxicity, which appeared to be related to disruption of
AD51 and therefore to HR activity (Figs. 3C–E and 4A and B),
s mediated by NHEJ. To address this question, we  disrupted
he XRCC4 gene, an essential co-factor of LigaseIV, in BRC4 cells.cells).
Differently from BRCA2+/− BRC4 cells (see Fig. 5), XRCC4/− BRC4
cells were indistinguishable from BRC4 cells as assessed by cell
growth and chromosomal aberration phenotypes (Fig. 6A and B).
These results indicate that NHEJ is neither involved in repairing
the DNA damage associated with high levels of BRC4 (in which
case XRCC4/− BRC4 cells are expected to have more severe phe-
notypes than BRC4 cells) nor responsible for the cytotoxicity and
chromosomal aberrations observed in BRC4 cells (in which case
XRCC4/− BRC4 cells would be expected to have alleviated pheno-
types).
3.7. BRC4 cytotoxicity is dependent on the RAD51 amount
In vitro and structural studies have shown the highly selective
binding of BRC4 peptide to RAD51 [6,8]. To address the selectiv-
ity of BRC4 for RAD51 in vivo and assess if this accounts for its
cytotoxicity (Fig. 3) and suppressive effect on HR (Fig. 4), we over-
expressed hsRAD51 in BRC4 cells (described as BRC4 + hsRAD51)
(Fig. 7A). In contrast to BRCA2 deﬁcient cells, whose growth rate
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Fig. 4. BRC4 suppresses homologous recombination and activates the G2/M checkpoint, but not the ATR replication checkpoint. (A) Homologous recombination (HR) repair
assay  using the I-SceI induced DSB formation at the DR-GFP reporter (see Fig. 2). Percentage of cells that underwent HR (measured as cells expressing GFP) is plotted. (B)
Rad51 focus formation. BRC4 cells were incubated in the presence or absence of Dox for 18 h. Cells were exposed to 500 ng/ml of MMC  for 1 h, then washed, and sampled after
1  h. At least 100 cells were scored for each preparation. Identical trends were observed in two  independent experiments. (C) Cell cycle distribution of BRC4 cells. Cells were
cultured in the presence of Dox for the indicated times, pulse-labeled with BrdU for 15 min, and harvested. The cells were stained with FITC anti-BrdU to detect BrdU uptake
and  with propidium iodide (PI) to detect DNA. The vertical axis represents BrdU uptake and horizontal axis represents total DNA. The gates represent SubG1 (apoptotic cells),
G1,  S and G2/M phase from left to right, in this order. Numbers show the percentage of cells falling in each gate. (D) BRC4 cells were cultured in the presence of Dox for 12 h,
further cultured in the presence or absence of Caffeine for 1 h and used for FACS analysis. (E) BRC4 cells were cultured in the presence of Dox for indicated times and whole
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nd cisplatin sensitivity are aggravated by RAD51 overexpression
35], excess amount of RAD51 completely rescued the lethality of
RC4-induced cells (Fig. 7B). While both BRCA2−/− cells and BRC4-
nduced cells show defects in RAD51 foci formation ([15] and see
ig. 4B), the above phenotype clearly separates BRCA2−/− cells from
RC4-induced cells. We  further conﬁrmed the selectivity of BRC4
or RAD51 by using a BRC4 variant, BRC4-A1504S, deﬁcient for
AD51 interaction [36]. Differently from BRC4, overexpression of
RC4-A1504S did not affect cell growth (Fig. 7C and D). These results,
aken together with the ones above, substantiate the notion that the
ytotoxicity associated with high levels of BRC4 arises speciﬁcally
rom its inhibitory binding to RAD51.AG and MCM7 (loading control) were detected by Western blotting.
3.8. BRC4 cytotoxicity is enhanced by DNA damaging agents, but
counteracted by RAD51 overexpression
RAD51 is essential for both cell survival and HR repair. Previ-
ous studies showed that BRC4 expression induces hypersensitivity
to -irradiation and DNA damaging agents such as CDDP [7,14].
We examined if, similarly to RAD51 deﬁciency, BRC4 induction
would affect not only cell growth (Fig. 3) but also the cellular
response to DNA damage. Because HR deﬁcient mutants such as
BRCA2 or RAD51 paralog knockout cells are highly sensitive to ola-
parib and camptothecin (CPT) [15,37], we incubated BRC4 cells with
either of these drugs in the presence or absence of Dox (Fig. 8A
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Fig. 5. BRC4 cytotoxicity depends on endogenous BRCA2. (A) Relative BRC4 expression level measured by qPCR. BRC4 cells and individually obtained 2 clones of BRCA2−/+
BRC4 cells were incubated in the presence or absence of Dox for 12 h and RNA was isolated. Isolated cDNA was  used for qPCR. (B) Expression of BRC4–FLAG peptide. Whole
cell  lysates were prepared from each cell line cultured in the presence of Dox for the indicated times. BRC4–FLAG and MCM7 (loading control) were detected by Western
b −/+ C4 ce 5
a xpres
B
a
p
g
t
(
l
i
s
o
i
d
h
B
o
B
alotting. (C) Growth curves. BRC4 or individually obtained 2 clones of BRCA2 BR
dded  at time 0. (D) Growth curves of mCherry positive cells. The number of cells e
RC4  and BRCA2−/+ BRC4 cells after treatment with Dox for 24 h.
nd B). We  used low concentrations of drugs, 0.5 M for ola-
arib and 5 nM for CPT, respectively, that do not impact on cell
rowth in WT cells. Indeed, BRC4 cells showed normal growth in
he absence of Dox, but BRC4-induced cells showed growth defects
see also Fig. 3C) that were exacerbated following treatment with
ow doses of these drugs (Fig. 8A and B). These results show that
nhibition of RAD51 function by BRC4 not only induces chromo-
omal damage, but also inhibits DNA repair [7,14]. Because RAD51
verexpression counteracted the cytotoxicity associated with BRC4
nduction (Fig. 7), we tested if it may  also counteract the DNA repair
efects of BRC4-induced cells. Differently from XRCC3−/− cells, used
ere as control because of their hypersensitivity to olaparib [37],
RC4 cells overexpressing RAD51 did not show high sensitivity to
laparib either in the absence or presence of Dox that induces
RC4 (Fig. 8C). These results indicate that both the cytotoxicity
nd the DNA repair defects associated with BRC4 induction arells (1 × 10 ) were inoculated in 1 ml  of medium and passaged every 12 h. Dox was
sing mCherry was  counted every 12 h. (E) Number of chromosomal aberrations in
related to its inhibitory effect on RAD51 and can be overcome by
increasing RAD51 amounts. These results thus suggest that HR is
proﬁcient in cells overexpressing both BRC4 and RAD51.  Surpris-
ingly, bright RAD51 foci induced by MMC  were abolished in cells
overexpressing both RAD51 and BRC4, whereas faint foci could still
be observed (Fig. 8D and E). Collectively, these results indicate
that BRC4 affects RAD51 polymerization even if RAD51 is overex-
pressed in the cells, but that the small RAD51 factories assembled
under these conditions are proﬁcient in mediating HR-mediated
DNA repair.
4. DiscussionConditional expression systems are powerful tools to study the
molecular mechanisms underlying the cytotoxicity associated with
speciﬁc proteins. Though the expression of target proteins should
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ells  after treatment with Dox for 24 h.
e completely repressed in ‘off state’, old Tet-On systems suffered
f leaky expression problems. In this study, we  applied the newly
eveloped Tet-On 3G system to chicken DT40 cells to study three
roteins. The expression of p53, I-SceI and BRC4 analyzed here was
ompletely repressed in the absence of Dox, whereas Dox addition
ig. 7. RAD51 overexpression rescues BRC4-induced cytotoxicity. (A) Expression of RAD5
ultured in the presence of Dox for the indicated times. RAD51, BRC4–FLAG and MCM7  
f  RAD51 show chicken and human RAD51, respectively. (B) Growth curves. BRC4 and in
 ml  of medium and passaged every 12 h. Dox was added at the time point labeled 0. (C)
 × 105 cells of the indicated genotype were inoculated in 1 ml  of medium and passaged 
nd  BRC4-A1504S cells. The number of cells expressing mCherry was counted every 12 h.) Growth curves. BRC4 and individually obtained 2 clones of XRCC4/− BRC4 cells
time labeled 0. (B) Number of chromosomal aberrations in BRC4 and XRCC4/− BRC4
induced expressions of these genes, thus establishing the Tet-On
3G system as suitable in DT40 research. Analysis of the phenotypes
associated with speciﬁc gene inductions also revealed novel aspects
on the mode of action of these proteins, particularly on the mode
of action of BRC4 and BRCA2, which are discussed below.
1 and BRC4–FLAG peptide. Whole cell lysates were prepared from each cell lines
(loading control) were detected by Western blotting. The upper and lower bands
dividually obtained 2 clones of BRC4 + hsRAD51 cells (1 × 105) were inoculated in
 Growth curves of BRC4 and BRC4-A1504S cells in the presence or absence of Dox.
every 12 h. Dox was  added at time 0. (D) Growth curves of mCherry positive BRC4
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Fig. 8. Rad51 overexpression rescues BRC4-induced homologous recombination repair defects. (A) and (B) growth curves. BRC4 cells (1 × 105) were inoculated in 1 ml  of
medium and passaged every 12 h. Dox and olaparib (A) or CPT (B) were added at time 0. (C) Sensitivity of indicated cells to olaparib. Dox was added 24 h before the
experiment. Cell survival percentage is displayed as the ratio of the number of surviving cells following olaparib treatment relative to the untreated control. Each line and
error  bar represents the mean value and SD from three independent experiments, respectively. (D) and (E) Rad51 focus formation. BRC4 cells and BRC4 + hsRAD51 cells were
incubated in the presence or absence of Dox for 20 h. Then cells were exposed to 500 ng/ml of MMC  for 6 h. Cytoplasmic RAD51 was washed out by pre-triton treatment prior
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High levels of BRC4 induced cell lethality and chromosomal type
reaks, reminiscent of the cytotoxicity associated with radiation
r RAD51 deﬁciencies (Fig. 3). Although none of the past stud-
es using BRC4 or other Brc repeats reported their cytotoxicity
7,8,14], the difference between the past studies and ours likely
omes from the expression levels of BRC4 as in our system high
mounts of BRC4 were induced (Fig. 3A). Another possible reason
or this new phenotype revealed here may  be due to species dif-
erences and related changes of critical residues within the BRC
epeats that impact on the strength of the BRC4–Rad51 interaction
38]. One of these examples is the V1532 residue of the BRC4 repeat
f human BRCA2, which is substituted by isoleucine in canine
pecies as well as in chicken BRCA2 [27]. In this vein, a recent study
eported enhanced binding of human BRC4 to RAD51 as well as Identical trends were observed in independently conducted experiments.
RAD51–DNA dissociation activity by replacing several amino acids
of BRC4 [36].
The cytotoxic effect of BRC4 was  further enhanced by the addi-
tion of low concentrations of olaparib and CPT (Fig. 8A and B),
indicating that BRC4 not only induces chromosomal breaks (Fig. 3E)
but that it also inhibits DNA repair simultaneously. The cytotoxic-
ity and inhibition of DNA repair by BRC4 completely depended on
RAD51 (Figs. 7 and 8). These results indicate that the target of BRC4
in cells is RAD51 and that BRC4 blocks RAD51 polymerization in
a competitive manner, together with endogenous BRCA2, likely in
a fashion that depends on the presence of other BRC repeats or C-
terminal residues of BRCA2 (Fig. 5). Alternatively, the effect of BRC4
induction may  be dependent on the endogenous BRC4 repeat. In this
regard, we  note that although the level of BRC4 mRNA induced by
A Repa
t
B
t
f
e
o
i
h
B
o
a
h
c
t
i
s
A
b
o
e
c
d
t
N
i
a
s
B
t
a
t
c
f
t
o
a
p
B
f
i
t
p
p
i
u
R
a
i
g
C
•
•
•
•
[
[
[
[
[
[
[
[
[T. Abe, D. Branzei / DN
he Tet-On 3G system was much higher than that of endogenous
RCA2 mRNA, the stability of the BRC4 peptide may  be lower than
hat of BRCA2. Further studies will be required to examine whether
ull length BRCA2 also inhibits RAD51 polymerization when over-
xpressed and to clarify a possible interplay between BRC4 and
ther BRCA2 domains in inhibiting RAD51-mediated DNA repair.
On the other hand, the interplay between BRC4 and BRCA2
n mediating cytotoxicity might reﬂect that distinct BRC repeats
ave separate activities in controlling genome integrity. Thus, while
RC4 plays a prominent role in regulating recombination repair,
ther BRC repeats may  be involved in controlling mitotic cell cycle
rrest, as it has been recently suggested for the BRC5 repeat of
uman BRCA2 [39]. While the BRC5 repeat itself is not conserved in
hicken BRCA2, it is possible that analogous mechanisms exist, or
hat other BRC repeats of chicken BRCA2 substitute for human BRC5
n what regards the interaction with factors implicated in cell divi-
ion. The ﬁnding that BRC4 overexpression induces both lesions and
TM-mediated cell-cycle arrest (Fig. 3) does not exclude this view,
ut other explanations remain possible. For instance, BRC4 and
ther domains of BRCA2 may  coordinately modulate DNA repair,
ither by similar or divergent roles. Interestingly, our results indi-
ate that NHEJ is not involved in processing BRC4-induced DNA
amage (Fig. 6), even in the absence of proper HR function. While
his could simply reﬂect a cell cycle-mediated down-regulation of
HEJ in G2, similarly to what has been reported in yeast [40–42],
t is also possible that other BRC repeats or domains of BRCA2 play
 role in suppressing alternative error-prone repair mechanisms,
uch as NHEJ, thus explaining the tumor suppressor function of
RCA2.
In addition to shedding new light on the BRCA2 and BRC4 func-
ion in vivo, the results of this study indicate that BRC4 is proﬁcient
t killing proliferating cancer cells as well as enhancing the cyto-
oxic effects of olaparib and CPT (Fig. 8A and B) in a manner
ompletely dependent on its inhibitory activity on RAD51. These
eatures of BRC4 may  be useful as a molecularly-targeted adjunc-
ive agent to enhance the effect of other anti-cancer drugs. It is
f note that over 35% of breast, ovarian and prostate carcinoma
ssociated with germline BRCA mutations do not respond to ola-
arib [43] nor do the sporadic breast cancers not associated with
RCA mutations. It is likely that (concomitant) inhibition of RAD51
unction in tumors that depend on HR for viability would lead to
mproved drug therapy. Although there is a considerable barrier
o efﬁciently deliver peptide medicines to the focus of disease in
atients, developments in drug delivery systems may  make such
eptide medications feasible in the future. Several speciﬁc RAD51
nhibitors have been reported recently [44–46]. Although it is still
nknown if similarly to BRC4 these reagents speciﬁcally inhibit
AD51, together with BRC4 peptides, they constitute attractive
nti-cancer drug candidates and useful in vitro tools to study the
nterplay between different repair pathways and their impact on
enome integrity.
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